SpringWorks Therapeutics Inc. - SWTX Income before deduction of interest, taxes and amortization

EBITDA dynamics on the GURU.Markets website demonstrate a stable development vector for SpringWorks Therapeutics (SWTX) within the secure US perimeter. The metric captures the current state of the parameter. The business relies on external contractors for molecule synthesis, fully outsourcing production. Meanwhile, the company is fighting for niche markets, contending with the resource superiority of large pharmaceutical behemoths.

SpringWorks - SWTX Operating profit EBITDA (period 07/04/2022 - 11/10/2026)

SpringWorks Therapeutics, Inc. (SWTX) - metric breakdowns and financial figures

- market value and analyst target forecast:

Market Price SpringWorks Therapeutics, Inc|SWTX - Consensus Target

- issuer market value details:

Market Value SpringWorks Therapeutics|SWTX - Real Price to Acquire Entire Company

- book capitalization information:

Book Price of a Share SpringWorks Therapeutics|SWTX - Book Capitalization|Market Capitalization to Book Value Ratio springworkstx.com|SWTX - Aggregate Company Assets

- company total debt and liquidity indicators:

All Debt to Shareholders' Equity Ratio SpringWorks Therapeutics|SWTX - Long-Term Debt to Capital|Short-Term Indebtedness to Equity SpringWorks Therapeutics Inc.|SWTX - Company Aggregate Debts|Debts to Book Value SpringWorks Therapeutics|SWTX - Company Long-Term Liabilities|Amount of Current Liabilities SpringWorks Therapeutics|Immediate Liquidity springworkstx.com

- financial results and valuation multiples details:

SWTX - Net Profit|Net Profit Forecast SpringWorks Therapeutics|SWTX - Price to Earnings Ratio|Future Price to Earnings Multiple springworkstx.com|SWTX - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio SpringWorks Therapeutics|SWTX - Operating profit EBITDA|Earnings per share for the trailing year SpringWorks Therapeutics|SWTX - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months springworkstx.com|SWTX - Earnings per share growth in current year|Expected earnings per share trend next year SpringWorks Therapeutics

Summary company analytics:SpringWorks Therapeutics

This indicator captures the actual cash flow from operating activities before deducting financial obligations and taxes, allowing for an assessment of operational capital management efficiency. By analyzing the EBITDA distribution across periods for SpringWorks Therapeutics (SWTX), an investor can correlate the monetization rates of proprietary oncology drugs with market conditions to avoid overvaluing the asset during an economic downturn.

Competitor analysis for SpringWorks Therapeutics

Genmab Corp (GMAB) - Profit before interest, taxes and amortization|EXEL: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization NUVL (nuvalent.com)|KYMR (Kymera) - Operating profit before deduction of amortization|IDYA: Company profit before taxes, interest and amortization|ELVN (Enliven Pharma) - Operating profit EBITDA|Operating profit EBITDA ORIC Corp|Profit before payment of interest, taxes and amortization Relay Therapeutics (RLAY)|NRIX (nurixtx.com) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA TYRA (Tyra Biosciences)|Operating profit before depreciation charges Verastem Oncology|Monte Rosa Tx - Operating profit EBITDA|Profit before interest, taxes and amortization Cullinan Corp|IMRX (Immuneering Corporation) - Operating profit before deduction of amortization|CCCC: Company profit before taxes, interest and amortization|BDTX (Black Diamond Therapeutics) - Operating profit EBITDA|Profit before interest, taxes and amortization Repare Therapeutics, Inc. RPTX|Operating profit EBITDA PMVP|karyopharm.com - Operating profit before amortization|Propanc Biopharma - Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization BGMS|AADI: Operating profit before deduction of amortization|Aileron Therapeutics - Company profit before taxes, interest and amortization|BPMC: Operating profit EBITDA|GlycoMimetics - Income before deduction of interest, taxes and amortization